Skip to main content
Top
Published in: Hepatology International 5/2020

01-09-2020 | ß-Blockers | Original Article

Functionality of beta-adrenergic receptors in patients with cirrhosis treated chronically with non-selective beta-blockers

Authors: Susana Almenara, Beatriz Lozano, Paula Gimenez, Ivan Herrera, Cayetano Miralles, Pablo Bellot, María Rodríguez, Rubén Francés, Jose M. Gonzalez-Navajas, Sonia Pascual, Pedro Zapater

Published in: Hepatology International | Issue 5/2020

Login to get access

Abstract

Background

In patients with cirrhosis, beta-adrenoceptors expressed on peripheral blood mononuclear cells have a reduced response to catecholamine stimulation. This study aimed to determine if chronic treatment with beta-blockers influences these changes.

Methods

Blood samples were collected from patients with cirrhosis treated in outpatient clinics. Differences in cyclic AMP production before and after stimulation of mononuclear cells with epinephrine and/or N-Formylmethionine-leucyl-phenylalanine (fMLP) was used as a marker of beta-adrenoceptors activity in patients treated (N = 19) versus not treated (N = 55) with beta-blockers. In addition, we studied the gene expression of different types of adrenoceptors and possible associations with the activity of beta-adrenoceptors, the serum concentrations of catecholamines and cytokines, and the presence of bacterial antigens such as DNA or gram-negative bacterial endotoxin in patients’ blood.

Results

The increase in intracellular cAMP concentrations after stimulation of adrenergic receptors with epinephrine was significantly higher in samples from patients treated with beta-blockers. Older patients showed lower responses to epinephrine stimulus, while the response increased linearly with the duration of the beta-blocker treatment. mRNA expression levels of adrenoceptors β1, β2, β3 and α1-A, B and D showed no significant differences according to treatment with beta-blockers. Neither serum cytokines nor catecholamines levels were significantly associated with the intracellular production of cAMP after adrenergic stimulation.

Conclusion

Chronic treatment with beta-blockers in patients with cirrhosis enables beta-adrenoceptors to respond to catecholamine stimulation irrespective of the degree of systemic adrenergic or immune activations of the patient at the time of sampling.

Graphic abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatol Baltim Md. 2006;43:S121–131.CrossRef Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatol Baltim Md. 2006;43:S121–131.CrossRef
2.
go back to reference Henriksen JH, Ring-Larsen H, Kanstrup IL, Christensen NJ. Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with decompensated cirrhosis. Gut. 1984;25:1034–43.CrossRef Henriksen JH, Ring-Larsen H, Kanstrup IL, Christensen NJ. Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with decompensated cirrhosis. Gut. 1984;25:1034–43.CrossRef
3.
go back to reference Floras JS, Legault L, Morali GA, Hara K, Blendis LM. Increased sympathetic outflow in cirrhosis and ascites: direct evidence from intraneural recordings. Ann Intern Med. 1991;114:373–80.CrossRef Floras JS, Legault L, Morali GA, Hara K, Blendis LM. Increased sympathetic outflow in cirrhosis and ascites: direct evidence from intraneural recordings. Ann Intern Med. 1991;114:373–80.CrossRef
4.
go back to reference Ramond M, Comoy E, Lebrec D. Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity. Br J Clin Pharmacol. 1986;21:191–6.CrossRef Ramond M, Comoy E, Lebrec D. Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity. Br J Clin Pharmacol. 1986;21:191–6.CrossRef
5.
go back to reference Hernández FT, Zapater P, De-Madaria E, Palazón JM, Pascual S, Irurzun J, et al. Functional status of β-2-adrenoceptor in isolated membranes of mature erythrocytes from patients with cirrhosis and oesophageal varices. Vascul Pharmacol. 2006;44:464–8.CrossRef Hernández FT, Zapater P, De-Madaria E, Palazón JM, Pascual S, Irurzun J, et al. Functional status of β-2-adrenoceptor in isolated membranes of mature erythrocytes from patients with cirrhosis and oesophageal varices. Vascul Pharmacol. 2006;44:464–8.CrossRef
6.
go back to reference Roca R, Esteban P, Zapater P, Inda M, Conte A, Gomez-Escolar L, et al. β2-adrenergic receptor functionality and genotype in two different models of chronic inflammatory disease: liver cirrhosis and osteoarthritis. Mol Med Rep. 2018;17:7987–95.PubMed Roca R, Esteban P, Zapater P, Inda M, Conte A, Gomez-Escolar L, et al. β2-adrenergic receptor functionality and genotype in two different models of chronic inflammatory disease: liver cirrhosis and osteoarthritis. Mol Med Rep. 2018;17:7987–95.PubMed
7.
go back to reference Such J. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology. 2002;36:135–41.CrossRef Such J. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology. 2002;36:135–41.CrossRef
8.
go back to reference Frances R. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut. 2004;53:860–4.CrossRef Frances R. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut. 2004;53:860–4.CrossRef
9.
go back to reference Guarner C, González-Navajas JM, Sánchez E, Soriando G, Francés R, Chiva M, et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology. 2006;44:633–9.CrossRef Guarner C, González-Navajas JM, Sánchez E, Soriando G, Francés R, Chiva M, et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology. 2006;44:633–9.CrossRef
10.
go back to reference González-Navajas JM, Bellot P, Francés R, Zapater P, Muñoz C, García-Pagán JC, et al. Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. J Hepatol. 2008;48:61–7.CrossRef González-Navajas JM, Bellot P, Francés R, Zapater P, Muñoz C, García-Pagán JC, et al. Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. J Hepatol. 2008;48:61–7.CrossRef
11.
go back to reference Francés R, Zapater P, González-Navajas JM, Muñoz C, Caño R, Moreu R, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology. 2008;47:978–85.CrossRef Francés R, Zapater P, González-Navajas JM, Muñoz C, Caño R, Moreu R, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology. 2008;47:978–85.CrossRef
12.
go back to reference Zapater P, Francés R, González-Navajas JM, de la Hoz MA, Moreu R, Pascual S, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology. 2008;48:1924–31.CrossRef Zapater P, Francés R, González-Navajas JM, de la Hoz MA, Moreu R, Pascual S, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology. 2008;48:1924–31.CrossRef
13.
go back to reference Gimenez P, Garcia-Martinez I, Francés R, Gonzalez-Navajas JM, Mauri M, Alfayate R, et al. Treatment with non-selective beta-blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis. Liver Int. 2018;38:2219–27.CrossRef Gimenez P, Garcia-Martinez I, Francés R, Gonzalez-Navajas JM, Mauri M, Alfayate R, et al. Treatment with non-selective beta-blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis. Liver Int. 2018;38:2219–27.CrossRef
14.
go back to reference Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int Off J Int Assoc Study Liver. 2015;35:362–9. Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int Off J Int Assoc Study Liver. 2015;35:362–9.
15.
go back to reference Bellinger DL, Lorton D. Autonomic regulation of cellular immune function. Auton Neurosci Basic Clin. 2014;182:15–411.CrossRef Bellinger DL, Lorton D. Autonomic regulation of cellular immune function. Auton Neurosci Basic Clin. 2014;182:15–411.CrossRef
16.
go back to reference Wahle M, Neumann RP, Moritz F, Krause A, Buttgereit F, Baerwald CGO. Beta2-adrenergic receptors mediate the differential effects of catecholamines on cytokine production of PBMC. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 2005;25:384–94.CrossRef Wahle M, Neumann RP, Moritz F, Krause A, Buttgereit F, Baerwald CGO. Beta2-adrenergic receptors mediate the differential effects of catecholamines on cytokine production of PBMC. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 2005;25:384–94.CrossRef
17.
go back to reference Mosenden R, Taskén K. Cyclic AMP-mediated immune regulation–overview of mechanisms of action in T cells. Cell Signal. 2011;23:1009–166.CrossRef Mosenden R, Taskén K. Cyclic AMP-mediated immune regulation–overview of mechanisms of action in T cells. Cell Signal. 2011;23:1009–166.CrossRef
18.
go back to reference Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52:595–638.PubMed Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52:595–638.PubMed
20.
go back to reference Thiele M, Albillos A, Abazi R, Wiest R, Gluud LL, Krag A. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver Int Off J Int Assoc Study Liver. 2015;35:2009–166. Thiele M, Albillos A, Abazi R, Wiest R, Gluud LL, Krag A. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver Int Off J Int Assoc Study Liver. 2015;35:2009–166.
21.
go back to reference Herrera I, Pascual S, Zapater P, Carnicer F, Bellot P, María PJ. The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2016;28:1194–7.CrossRef Herrera I, Pascual S, Zapater P, Carnicer F, Bellot P, María PJ. The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2016;28:1194–7.CrossRef
22.
go back to reference Henriksen JH, Møller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol. 1998;29:328–41.CrossRef Henriksen JH, Møller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J Hepatol. 1998;29:328–41.CrossRef
23.
go back to reference Tage-Jensen U, Henriksen JH, Christensen E, Widding A, Ring-Larsen H, Christensen NJ. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J Hepatol. 1988;6:350–8.CrossRef Tage-Jensen U, Henriksen JH, Christensen E, Widding A, Ring-Larsen H, Christensen NJ. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J Hepatol. 1988;6:350–8.CrossRef
24.
go back to reference Gaudin C, Braillon A, Moreau R, Roulot D, Bacq Y, Hadengue A, et al. Relation between plasma catecholamines, the severity of the liver disease and hemodynamics in patients with cirrhosis. Gastroenterol Clin Biol. 1989;13:701–6.PubMed Gaudin C, Braillon A, Moreau R, Roulot D, Bacq Y, Hadengue A, et al. Relation between plasma catecholamines, the severity of the liver disease and hemodynamics in patients with cirrhosis. Gastroenterol Clin Biol. 1989;13:701–6.PubMed
25.
go back to reference Bendtsen F, Henriksen JH, Sørensen TI, Christensen NJ. Effect of oral propranolol on circulating catecholamines in cirrhosis: relationship to severity of liver disease and splanchnic haemodynamics. J Hepatol. 1990;10:198–204.CrossRef Bendtsen F, Henriksen JH, Sørensen TI, Christensen NJ. Effect of oral propranolol on circulating catecholamines in cirrhosis: relationship to severity of liver disease and splanchnic haemodynamics. J Hepatol. 1990;10:198–204.CrossRef
26.
go back to reference Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, et al. TGF-β signalling and liver disease. FEBS J. 2016;283:2219–32.CrossRef Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, et al. TGF-β signalling and liver disease. FEBS J. 2016;283:2219–32.CrossRef
27.
go back to reference He J, Liu Y. Serum TGF-β1: a potential biomarker for early detection of hepatocellular carcinoma. EBioMedicine. 2016;12:4–5.CrossRef He J, Liu Y. Serum TGF-β1: a potential biomarker for early detection of hepatocellular carcinoma. EBioMedicine. 2016;12:4–5.CrossRef
28.
go back to reference Watanabe Y, Iwamura A, Shimada YJ, Wakai K, Tamakoshi A, Iso H. Transforming growth factor-β1 as a predictor for the development of hepatocellular carcinoma: a nested case-controlled study. EBioMedicine. 2016;12:68–71.CrossRef Watanabe Y, Iwamura A, Shimada YJ, Wakai K, Tamakoshi A, Iso H. Transforming growth factor-β1 as a predictor for the development of hepatocellular carcinoma: a nested case-controlled study. EBioMedicine. 2016;12:68–71.CrossRef
30.
go back to reference Mandorfer M, Bota S, Schwabl P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146:1680–90 (e1).CrossRef Mandorfer M, Bota S, Schwabl P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146:1680–90 (e1).CrossRef
Metadata
Title
Functionality of beta-adrenergic receptors in patients with cirrhosis treated chronically with non-selective beta-blockers
Authors
Susana Almenara
Beatriz Lozano
Paula Gimenez
Ivan Herrera
Cayetano Miralles
Pablo Bellot
María Rodríguez
Rubén Francés
Jose M. Gonzalez-Navajas
Sonia Pascual
Pedro Zapater
Publication date
01-09-2020
Publisher
Springer India
Published in
Hepatology International / Issue 5/2020
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-020-10083-5

Other articles of this Issue 5/2020

Hepatology International 5/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.